Review of the structural and dynamic mechanisms of PPAR γ partial agonism

PPAR Research

Volumn 2015, Issue , 2015, Pages

  Kroker, Alice J ^a   Bruning, John B ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; AMORFRUTIN 2; AMORFRUTIN B; ARHALOFENATE; BALAGLITAZONE; BENZIMIDAZOLE DERIVATIVE; CEROCOSPORAMIDE DERIVATIVE; GQ 16; GW 0072; INDOLE DERIVATIVE; NETOGLITAZONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; RETINOID X RECEPTOR; ROSIGLITAZONE; SULFONAMIDE; T 2384; TELMISARTAN; THIAZOLIDINE DERIVATIVE; TROGLITAZONE; UNCLASSIFIED DRUG;

DRUG RECEPTOR BINDING; HUMAN; HYDROGEN BOND; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; REVIEW;

EID: 84942333215     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2015/816856     Document Type: Review

References (72)

1. P. Tontonoz and B.M. Spiegelman, "Fat and beyond: the diverse biology of PPAR," Annual Review of Biochemistry, vol. 77, pp. 289-312, 2008.
2. O. Braissant, F. Foufelle, C. Scotto, M. Dauc?, and W. Wahli, "Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat," Endocrinology, vol. 137, no. 1, pp. 354-366, 1996.
3. I. Issemann andS.Green, "Activationofamember of the steroid hormone receptor superfamily by peroxisome proliferators," Nature, vol. 347, no. 6294, pp. 645-650, 1990.
4. K. L. Gearing, M. Gttlicher, M. Teboul, E. Widmark, and J.-?A. Gustafsson, "Interaction of the peroxisome-proliferatoractivated receptor and retinoid X receptor," Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 4, pp. 1440-1444, 1993.
5. P. Tontonoz, E. Hu, and B. M. Spiegelman, "Stimulation of adipogenesis in fibroblasts by PPAR2, a lipid-activated transcription factor," Cell, vol. 79, no. 7, pp. 1147-1156, 1994.
6. R. Saladin, L. Fajas, S. Dana, Y. D. Halvorsen, J. Auwerx, and M. Briggs, "Differential regulation of peroxisome proliferator activated receptor 1 (PPAR1) and PPAR2 messenger RNA expression in the early stages of adipogenesis," Cell Growth and Differentiation, vol. 10, no. 1, pp. 43-48, 1999.
7. D. B. Savage, "PPAR as a metabolic regulator: insights from genomics and pharmacology," Expert Reviews in Molecular Medicine, vol. 7, no. 1, pp. 1-6, 2005.
8. E. D. Rosen, P. Sarraf,A.E.Troy et al., "PPARgamma is required for the differentiation of adipose tissue in vivo and in vitro," Molecular Cell, vol. 4, no. 4, pp. 611-617, 1999.
9. A. S. Banks, F. E. McAllister, J. P. G. Camporez et al., "An ERK/Cdk5 axis controls the diabetogenic actions of PPARgamma," Nature, vol. 517, no. 7534, pp. 391-395, 2015.
10. J. H. Choi, A. S. Banks, J. L. Estall et al., "Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPAR by Cdk5," Nature, vol. 466, no. 7305, pp. 451-456, 2010.
11. J. H. Choi, A. S. Banks, T. M. Kamenecka et al., "Antidiabetic actions of a non-agonist PPAR ligand blocking Cdk5-mediated phosphorylation," Nature, vol. 477, no. 7365, pp. 477-481, 2011.
12. V. Zoete, A. Grosdidier, and O. Michielin, "Peroxisome proliferator-activated receptor structures: ligand specificity, molecular switch and interactions with regulators," Biochimica et Biophysica Acta-Molecular and Cell Biology of Lipids, vol. 1771, no. 8, pp. 915-925, 2007.
13. L. Mouchiroud, L. J. Eichner, R. J. Shaw, and J. Auwerx, "Transcriptional coregulators: fine-tuning metabolism," Cell Metabolism, vol. 20, no. 1, pp. 26-40, 2014.
14. V. Chandra, P. Huang, Y. Hamuro et al., "Structure of the intact PPAR--RXR- nuclear receptor complex on DNA," Nature, vol. 456, no. 7220, pp. 350-356, 2008.
15. S. Hummasti and P. Tontonoz, "The peroxisome proliferatoractivated receptor N-terminal domain controls isotype-selective gene expression and adipogenesis," Molecular Endocrinology, vol. 20, no. 6, pp. 1261-1275, 2006.
16. A. Bugge and S. Mandrup, "Molecular mechanisms and genome-wide aspects of PPAR subtype specific transactivation," PPAR Research, vol. 2010, Article ID 169506, 12 pages, 2010.
17. A. IJpenberg, E. Jeannin,W.Wahli, and B. Desvergne, "Polarity and specific sequence requirements of peroxisome proliferatoractivated receptor (PPAR)/retinoid X receptor heterodimer binding toDNA.Afunctional analysis of themalic enzyme gene PPAR response element,"The Journal of Biological Chemistry, vol. 272, no. 32, pp. 20108-20117, 2010.
18. C. Helsen and F. Claessens, "Looking at nuclear receptors from a newangle,"Molecular and Cellular Endocrinology, vol. 382, no. 1, pp. 97-106, 2014.
19. R. T. Nolte, G. B. Wisely, S. Westin et al., "Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-," Nature, vol. 395, no. 6698, pp. 137-143, 1998.
20. F. Gilardi and B. Desvergne, "RXRs: collegial partners," Sub-Cellular Biochemistry, vol. 70, pp. 75-102, 2014.
21. N. S. C. Eager, A. Rowe, and P. M. Brickell, "A member of the chicken RXR family of nuclear receptors activates transcription in response to retinoic acid," FEBS Letters, vol. 292, no. 1-2, pp. 103-106, 1991.
22. M. Schupp and M. A. Lazar, "Endogenous ligands for nuclear receptors: digging deeper," The Journal of Biological Chemistry, vol. 285, no. 52, pp. 40409-40415, 2010.
23. B. M. Forman, P. Tontonoz, J. Chen, R. P. Brun, B. M. Spiegelman, and R. M. Evans, "15-deoxy-? 12,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR," Cell, vol. 83, no. 5, pp. 803-812, 1995.
24. T. Waku, T. Shiraki, T. Oyama, K.Maebara, R. Nakamori, and K. Morikawa, "The nuclear receptor PPAR individually responds to serotonin-and fatty acid-metabolites," EMBOJournal, vol. 29, no. 19, pp. 3395-3407, 2010.
25. G. C. Mannino and G. Sesti, "Individualized therapy for type 2 diabetes: clinical implications of pharmacogenetic data," Molecular Diagnosis and Therapy, vol. 16, no. 5, pp. 285-302, 2012.
26. C. Day, "Thiazolidinediones: a new class of antidiabetic drugs," Diabetic Medicine, vol. 16, no. 3, pp. 179-192, 1999.
27. S. L. Pearson, M. A. Cawthorne, J. C. Clapham et al., "The thiazolidinedione insulin sensitiser, BRL 49653, increases the expression of PPAR-and aP2 in adipose tissue of high-fat-fed rats," Biochemical and Biophysical Research Communications, vol. 229, no. 3, pp. 752-757, 1996.
28. L. S. Phillips, G. Grunberger, E. Miller, R. Patwardhan, E. B. Rappaport, andA. Salzman, "Once-and twice-daily dosingwith rosiglitazone improves glycemic control in patients with type 2 diabetes," Diabetes Care, vol. 24, no. 2, pp. 308-315, 2001.
29. T. Ikeda, "Drug-induced idiosyncratic hepatotoxicity: prevention strategy developed after the troglitazone case," Drug Metabolismand Pharmacokinetics, vol. 26,no. 1, pp. 60-70, 2011.
30. N. S. B. Rawson, "Review of the quality of observational studies of the association between rosiglitazone and acute myocardial infarction," Journal of Population Therapeutics and Clinical Pharmacology, vol. 21, no. 2, pp. e214-e232, 2014.
31. R. E. J. Ryder, "Pioglitazone has a dubious bladder cancer risk but an undoubted cardiovascular benefit," Diabetic Medicine, vol. 32, no. 3, pp. 305-313, 2015.
32. S. Horita, M. Nakamura, N. Satoh, M. Suzuki, and G. Seki, "Thiazolidinediones and edema: recent advances in the pathogenesis of thiazolidinediones-induced renal sodium retention," PPAR Research, vol. 2015, Article ID 646423, 7 pages, 2015.
33. Y. Endo, M. Suzuki, H. Yamada et al., "Thiazolidinediones enhance sodium-coupled bicarbonate absorption from renal proximal tubules via PPAR-dependent nongenomic signaling," Cell Metabolism, vol. 13, no. 5, pp. 550-561, 2011.
34. J. P. Berger, A. E. Petro, K. L.Macnaul et al., "Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator," Molecular Endocrinology, vol. 17, no. 4, pp. 662-676, 2003.
35. S. M. Rangwala andM. A. Lazar, "The dawn of the SPPARMs?" Sciences STKE, vol. 2002, no. 121, p. pe9, 2002.
36. A. M. DePaoli, L. S. Higgins, R. R. Henry, C. Mantzoros, and F. L. Dunn, "Can a selective PPAR modulator improve glycemic control in patients with type 2 diabetes with fewer side effects compared with pioglitazone?" Diabetes Care, vol. 37, no. 7, pp. 1918-1923, 2014.
37. H. Kakuta, E. Kurosaki, T. Niimi et al., "Distinct properties of telmisartan on agonistic activities for peroxisome proliferatoractivated receptor among clinically used angiotensin II receptor blockers: drug-target interaction analyses," Journal of Pharmacology and Experimental Therapeutics, vol. 349, no. 4, pp. 10-20, 2014.
38. A. Laghezza,R.Montanari, A. Lavecchia et al., "Onthemetabolically active form of metaglidasen: improved synthesis and investigation of its peculiar activity on peroxisome proliferatoractivated receptors and skeletal muscles," ChemMedChem, vol. 10, no. 3, pp. 555-565, 2015.
39. R. Agrawal, P. Jain, and S. N. Dikshit, "Balaglitazone: a second generation peroxisome proliferator-activated receptor (PPAR) gamma () agonist," Mini-Reviews in Medicinal Chemistry, vol. 12, no. 2, pp. 87-97, 2012.
40. O. P. Lazarenko, S. O. Rzonca, L. J. Suva, and B. Lecka-Czernik, "Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat," Bone, vol. 38, no. 1, pp. 74-84, 2006.
41. J. L. Oberfield, J. L. Collins, C. P. Holmes et al., "A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation," Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 11, pp. 6102-6106, 1999.
42. T. ?Ostberg, S. Svensson, G. Sel?n et al., "A new class of peroxisomeproliferator-activated receptor agonistswith a novel binding epitope shows antidiabetic effects," Journal of Biological Chemistry, vol. 279, no. 39, pp. 41124-41130, 2004.
43. F. Zhang, B. E. Lavan, and F.M. Gregoire, "Selective modulators of PPAR-activity: molecular aspects related to obesity and side-effects," PPAR Research, vol. 2007, Article ID 32696, 7 pages, 2007.
44. L. S. Higgins and C. S.Mantzoros, "The development of INT131 as a selective PPARgamma modulator: approach to a safer insulin sensitizer," PPAR Research, vol. 2008, Article ID 936906, 9 pages, 2008.
45. T. Allen, F. Zhang, S. A.Moodie et al., "Halofenate is a selective peroxisome proliferator-activated receptor gamma modulator with antidiabetic activity," Diabetes, vol. 55,no. 9, pp. 2523-2533, 2006.
46. B. A. Johnson, E. M. Wilson, Y. Li, D. E. Moller, R. G. Smith, and G. Zhou, "Ligand-induced stabilization of PPAR monitored by NMR spectroscopy: implications for nuclear receptor activation," Journal of Molecular Biology, vol. 298, no. 2, pp. 187-194, 2000.
47. J. B. Bruning, M. J. Chalmers, S. Prasad et al., "Partial agonists activate PPAR using a helix 12 independent mechanism," Structure, vol. 15, no. 10, pp. 1258-1271, 2007.
48. J.-P. Renaud, N. Rochel, M. Ruff et al., "Crystal structure of the RAR-ligand-binding domain bound to all-trans retinoic acid," Nature, vol. 378, no. 6558, pp. 681-689, 1995.
49. M. V. Liberato, A. S. Nascimento, S. D. Ayers et al., "Medium chain fatty acids are selective peroxisome proliferator activated receptor (PPAR) activators and Pan-PPAR partial agonists," PLoS ONE, vol. 7, no. 5,Article ID e36297, 2012.
50. M. Einstein, T. E. Akiyama, G. A. Castriota et al., "The differential interactions of peroxisome proliferator-activated receptor ligandswith Tyr473 is a physical basis for their unique biological activities," Molecular Pharmacology, vol. 73, no. 1, pp. 62-74, 2008.
51. S. D. Debenham, A. Chan, F. W. Lau et al., "Highly functionalized 7-azaindoles as selective PPAR gamma modulators," Bioorganic and Medicinal Chemistry Letters, vol. 18, no. 17, pp. 4798-4801, 2008.
52. M. Sime, A. C. Allan, P. Chapman et al., "Discovery of GSK1997132B a novel centrally penetrant benzimidazole PPARgamma partial agonist," Bioorganic and Medicinal Chemistry Letters, vol. 21, no. 18, pp. 5568-5572, 2011.
53. Y. Amano, T. Yamaguchi, K. Ohno et al., "Structural basis for telmisartan-mediated partial activation of PPAR gamma," Hypertension Research, vol. 35, no. 7, pp. 715-719, 2012.
54. K.Wakabayashi, S.Hayashi, Y.Matsui et al., "Pharmacology and in vitro profiling of a novel peroxisome proliferator-activated receptor ligand, cerco-A," Biological and Pharmaceutical Bulletin, vol. 34, no. 7, pp. 1094-1104, 2011.
55. A.Furukawa, T. Arita, S. Satohet al., "Discoveryofanovel selective PPAR modulator from (-)-cercosporamide derivatives," Bioorganic and Medicinal Chemistry Letters, vol. 20, no. 7, pp. 2095-2098, 2010.
56. A. Furukawa, T. Arita, T. Fukuzaki et al., "Synthesis and biological evaluation of novel (?)-cercosporamide derivatives as potent selective PPAR modulators," European Journal of Medicinal Chemistry, vol. 54, pp. 522-533, 2012.
57. A. Furukawa, T. Arita, T. Fukuzaki et al., "Substituents at the naphthalene C3 position of (?)-cercosporamide derivatives significantly affect themaximal efficacy as PPAR partial agonists," Bioorganic and Medicinal Chemistry Letters, vol. 22, no. 3, pp. 1348-1351, 2012.
58. I.-L. Lu, C.-F. Huang, Y.-H. Peng et al., "Structure-based drug design of a novel family of PPAR partial agonists: virtual screening, X-ray crystallography, and in vitro/in vivo biological activities," Journal of Medicinal Chemistry, vol. 49, no. 9, pp. 2703-2712, 2006.
59. Y. Li, J. Zhang, F. J. Schopfer et al., "Molecular recognition of nitrated fatty acids by PPAR," Nature Structural and Molecular Biology, vol. 15, no. 8, pp. 865-867, 2008.
60. A. Motani, Z. Wang, J. Weiszmann et al., "INT131: a selective modulator of PPAR," Journal ofMolecular Biology, vol. 386, no. 5, pp. 1301-1311, 2009.
61. A. A. Amato, S. Rajagopalan, J. Z. Lin et al., "GQ-16, a novel peroxisome proliferator-activated receptor (PPAR) ligand, promotes insulin sensitization withoutweight gain,"TheJournal of Biological Chemistry, vol. 287, no. 33, pp. 28169-28179, 2012.
62. E. Burgermeister, A. Schnoebelen, A. Flament et al., "A novel partial agonist of peroxisome proliferator-activated receptorgamma (PPARgamma) recruits PPARgamma-coactivator-1alpha, prevents triglyceride accumulation, and potentiates insulin signaling in vitro,"Molecular Endocrinology, vol. 20, no. 4, pp. 809-830, 2006.
63. G. Pochetti, C. Godio, N. Mitro et al., "Insights into the mechanism of partial agonism: crystal structures of the peroxisome proliferator-activated receptor ligand-binding domain in the complex with two enantiomeric ligands," Journal of Biological Chemistry, vol. 282, no. 23, pp. 17314-17324, 2007.
64. R.P.Trump, J.E.Cobb, B. G. Shearer et al., "Co-crystal structure guided array synthesis of PPARgamma inverse agonists," Bioorganic and Medicinal Chemistry Letters, vol. 17, no. 14, pp. 3916-3920, 2007.
65. C.Weidner, J. C. de Groot, A. Prasad et al., "Amorfrutins are potent antidiabetic dietary natural products," Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 19, pp. 7257-7262, 2012.
66. R. Montanari, F. Saccoccia, E. Scotti et al., "Crystal structure of the peroxisome proliferator-activated receptor (PPAR) ligand binding domain complexed with a novel partial agonist: a new region of the hydrophobic pocket could be exploited for drug design," Journal ofMedicinal Chemistry, vol. 51, no. 24, pp. 7768-7776, 2008.
67. Y. Li, Z.Wang, N. Furukawa et al., "T2384, a novel antidiabetic agent with unique peroxisome proliferator-activated receptor binding properties,"The Journal of Biological Chemistry, vol. 283, no. 14, pp. 9168-9176, 2008.
68. A. Riu, M.Grimaldi,A. leMaire et al., "Peroxisome proliferatoractivated receptor is a target for halogenated analogs of bisphenol A," Environmental Health Perspectives, vol. 119, no. 9, pp. 1227-1232, 2011.
69. A. Casimiro-Garcia, G. F. Filzen, D. Flynn et al., "Discovery of a series of imidazo[4,5-b]pyridines with dual activity at angiotensin II type 1 receptor and peroxisome proliferatoractivated receptor-gamma," Journal ofMedicinal Chemistry, vol. 54, no. 12, pp. 4219-4233, 2011.
70. M. Ohashi, T. Oyama, E. W. Putranto et al., "Design and synthesis of a series of -benzyl phenylpropanoic acid-type peroxisome proliferator-activated receptor (PPAR) gamma partial agonists with improved aqueous solubility," Bioorganic and Medicinal Chemistry, vol. 21, no. 8, pp. 2319-2332, 2013.
71. J. C. de Groot, C.Weidner, J. Krausze et al., "Structural characterization of amorfrutins bound to the peroxisome proliferatoractivated receptor ," Journal ofMedicinal Chemistry, vol. 56,no. 4, pp. 1535-1543, 2013.
72. A. Casimiro-Garcia, R. J. Heemstra, C. F. Bigge et al., "Design, synthesis, and evaluation of imidazo[4,5-c]pyridin-4-one derivatives with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-gamma," Bioorganic and Medicinal Chemistry Letters, vol. 23, no. 3, pp. 767-772, 2013.